N.J. Mørk

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

The Combination of Etanercept and Methotrexate Increases the Effectiveness of Treatment in Active Psoriasis Despite Inadequate Effect of Methotrexate Therapy

Claus Zachariae, N.J. Mørk, Timo Reunala et al. · Acta Dermato Venereologica · 2008 · 147 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and skeletal side effects of two years' acitretin treatment.

N.J. Mørk, A Kolbenstvedt, Joar Austad · Acta Dermato Venereologica · 1992 · 36 citations · Full text

Medicine, Dermatology, Pharmacotherapy +6

Conversion of Psoriasis Patients from the Conventional Formulation of Cyclosporin A to a New Microemulsion Formulation: A Randomized, Open, Multicentre Assessment of Safety and Tolerability

H Zachariae, Beatrice Abrams, S.S. Bleehen et al. · Dermatology · 1998 · 16 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Implementing Best Practice in Psoriasis: A Nordic Expert Group Consensus

Knud Kragballe, Robert Gniadecki, N.J. Mørk et al. · Acta Dermato Venereologica · 2014 · 14 citations · Full text

Pharmacy, Dermatology, Good Clinical Practice +14